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Abstract 
It is well known that hepatitis B virus (HBV) infection is endemic in Nigeria. However, increased rubella 
susceptibility has been shown in patients from the Asian pacific region where chronic HBV infection is endemic. 
This study was carried out to assess the relationship between chronic HBV infection and rubella susceptibility in 
obstetric population aged 15–47 years attending Antenatal Clinic at Muhammad Abdullahi Wase Specialist 
Hospital Kano, Nigeria. From a total of 288 patients screened, 31 (10.76%) were reactive for HBsAg, meanwhile 
50 (17.36%) were reactive to rubella IgM. Among the 31 infected patients 15 (48.39%) were from 20 – 24 years 
age bracket representing the most  susceptible age group while the infection rate was lowest (0.35%) in 45 – 49  
age group (P = 0.00). The results of serological markers shows that HBsAg (+) was found in all 31 subjects 
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(100%), anti HBs (+) 0 (0.00%), HBeAg (+) 3 (9.68%); anti HBe (+) and anti HBc (+) 24 (77.42%) respectively 
(P = 0.09). The study of liver enzymes activity among the HBV positive patients shows abnormal Alanine 
Aminotransferase (ALT) and Aspartate Aminotransferase (AST) among HBsAg (+) and HBeAg (+) group. 
However, abnormal Alkaline phospatase (ALP) was found to be non-significantly different between HBsAg (+) 
and HBeAg (+) vsHBsAg (+) and HBeAg (-) groups (P=0.00). Moreover, obstetric histories such as abortion still 
birth and neonatal deaths among various age groups with respect to rubella was also studied, it implies that  out of 
the 50 reactive patients, 35(12.15%) had a previous abnormal obstetric history (P=0.02). In a comparative study 
conducted, it was observed that HBV carriers were (25.81%) susceptible to rubella as against (12.91%) observed 
in HBV free subjects (positive correlation). The study demonstrates strong associations between chronic HBV 
infection and rubella susceptibility among the studied population. 
Keywords: Chronic; Hepatitis B virus; Infection; Obstetrics; Rubella; Sero-markers; Susceptibility. 
1. Introduction  
Early detection of infections such as Human immunodeficiency virus (HIV), hepatitis B, syphilis and rubella in 
pregnancy can lead to health gains for both mother and child [1,2]. Effective treatment and intervention can be 
offered to prevent onward transmission of HIV and hepatitis B [3,4] and reduce the risk of congenital infectious 
diseases [2].  
Hepatitis B virus (HBV) is a DNA virus causing hepatitis in humans. It accounts for 400 million chronic 
infections worldwide [5] and is hyperendemic in sub-Saharan Africa and Asia [6,7]. It is thought to be the main 
etiological factor in over 75% of chronic liver diseases [7]. Transmission of HBV results from exposure to 
infected blood or body fluids, unprotected sexual contact, blood transfusion, the use of contaminated needles 
and syringes, and vertical transmission (from mother to child) [8]. The risk of Peri-natal infection among infants 
born to HBeAg-negative mothers ranges from 10% to 40%, with 40%-70% of these infected remain chronically 
infected [9]. Children born to HBsAg-positive mothers who do not become infected during the Peri-natal period 
remain at a high risk of infection during early childhood. HBV-related liver diseases or hepatocellular 
carcinoma (HCC) are responsible for over a million deaths per year and represent 5-10% cases of liver 
transplantation [10,11]. HCC is one of the most common cancers worldwide, HBV being responsible for at least 
75% occurrences [9]. 
Testing for HBV infection in pregnancy has been of importance in respect of morbidity and mortality of the host 
(pregnant women), likewise its effect on the process of parturition, and the risk of vertical transmission [12]. 
The contaminated new-born most often remains a chronic carrier with the consequences of liver cirrhosis, and 
HCC. Mother-to-child transmission can be avoided by vaccination of the newborn [12]. This intervention to stop 
vertical transmission can only be applied when the status of the pregnant woman is known. 
 Rubella, commonly known as German measles is a disease caused by the rubella virus. The name “rubella” is 
derived from the Latin, meaning little red. It is generally a mild illness and serious complications are rare. 
However, primary maternal rubella virus infection during the first trimester of pregnancy carries a high risk for 
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the development of congenital rubella syndrome (CRS) with characteristic malformations of the heart, eye and 
ear or even death of the fetus.  As of December 2012, a total of 132 (68%) WHO member states had introduced 
rubella-containing vaccine (RCV), a 33% increase from 99 member states in 2000. A total of 94,030 rubella 
cases were reported to WHO in 2012 from 174 member states, an 86% decrease from the 670,894 cases reported 
in 2000 from 102 member states [13]. In Nigeria, previous studies on pregnant women revealed rubella IgG 
prevalence of 68.50% in Ibadan [14], 54.10% in Maiduguri [15] and 76.00% in Lagos [16]. In western Nigeria, 
[17] showed that an average of 68.00% of the Nigerian population possessed rubella antibody [18]. Therefore on 
the average, 66.20% of pregnant women in Nigeria are already immune to rubella infection probably due to 
subclinical or clinical exposure to the virus as there is no policy for immunization against it and there is a 
33.80% susceptible population [18]. To prevent prenatal HBV infection and future cases of CRS, the advisory 
committee on immunization practices, the American Academy of pediatrics (AAP) and American college of 
obstetrics and Gynecology recommended routine prenatal screening to identify women who carry the hepatitis B 
surface antigen (HBsAg) and rubella IgG and post-partum vaccination of women who lack evidence of rubella 
immunity [19,20,55].     
2. Materials and Methods 
2.1. Study area   
The investigation was carried out at antenatal clinic, Muhammad Abdullahi Wase Specialist Hospital Kano. It is 
one of the reference hospitals in the state where people from various parts of the state and neighboring states of 
various backgrounds attend.   
2.2 Study Population 
A total of 288 pregnant women of homogenous sex and of different age groups, ethnicities, educational and 
socio-economic status, who filled the consent forms were recruited for this study using standard epidemiological 
formula. Thirty one control samples were used for comparison based on HBsAg  sero-positive cases. 
2.3 Study Design 
 A descriptive study was used to design a cross-sectional (prevalence) survey which was carried out according to 
the ethical standard for human experimentation. An ethical clearance was obtained from Hospitals Management 
Board Kano State.  
2.4 Limitations 
Some obstacles such as time frame, short of funding and compliance were encountered along the course of the 
research 
2.5 Virological Examinations 
2.5.1 Screening for Hepatitis B surface Antigen (HBsAg)  
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All the samples were tested for Hepatitis B surface antigen (HBsAg) using rapid chromatographic immunoassay 
for the qualitative detection of HBsAg. The test strips and sera were allowed to equilibrate to room temperature 
(25-300C) prior to testing. 
• Procedure 
The test strip contains anti HBsAg particles and anti – HBsAg coated on the   membrane. The tape from the test 
card was peeled off and the test strip was stocked in the middle of test card with arrows pointing down on the 
test card. The dropper was held vertically and 3 drops of the serum (75µL) was transferred onto the “specimen 
pad” of the test strip. A drop of buffer (40µL) was added and the appearance of the colored line(s) was observed 
within 15 minutes [21].   
2.5.2 Test for Serological Markers  
The one step cassette style HBV test (combo) is rapid test based on the principle of immunoassay combined 
colloid gold technology. The HBV test is a diagnostic device to detect the 5 markers (HBsAg, HBeAg, anti-
HBe, anti-HBc and anti-HBs) associated with Hepatitis B virus infection.  
• Procedure 
The test kit was removed from the pouch and placed horizontally on a desk. Three drops of the serum sample 
was added into each well marked 1-5 and three drops of buffer was also added in each well. The results were 
read after 15 minutes [21].   
2.6 Biochemical Analysis             
2.6.1 Alanine Amino Transferase (ALT)             
• Procedure  
About 0.1ml of serum sample was placed in one tube (tube 1); another 0.1ml of standard solution was also 
added into a separate tube (tube 2). 0.5ml of phosphate buffer solution (R1) was then added to 
both tube 1 and 2. Five milliliter (5.0ml) of 2, 4 – dinitrophenyl hydrazine solution (R2) was also added to both 
tube 1 and 2. The preparation was mixed and incubated for 30 minutes at 30oC. 5.0ml of sodium hydroxide 
(NaOH) was added and incubated for exactly 20 minutes at 25oC. Another 5.0ml of (NaOH) was added to both 
tubes. The preparation was mixed and read spectrophotometrically at 546nm wavelength [22]. 
2.6.2 Aspartate Aminostransferase (AST) 
• Procedure  
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About 0.1ml of serum sample was placed in one tube (tube 1); another 0.1ml of standard solution was added 
into a separate tube (tube 2). 0.5ml of phosphate buffer solution (R1) was then added to both tube 1 and 2. Then 
5.0ml of 2, 4 – dinitrophenyl hydrazine solution (R2) was added into the tubes. The preparation was mixed and 
incubated at 30oC for 30 minutes. Then 5.0ml of sodium hydroxide (NaOH) was added and incubated at 25oC 
for 20 minutes. Another 5.0ml of (NaOH) was added to both the tubes. The preparation was mixed and read 
spectrophotometrically at 546nm wavelength [22] 
2.6.3 Alkaline Phosphatase (ALP) 
• Procedure  
About 0.5ml of alkaline phosphate reagent was placed in a tube labeled T and another 0.5ml in another tube 
labeled B. 50μl of serum sample was added to tube T, while 50ul of reagent blank was also added to tube B. The 
preparation was mixed and incubated at 37oC for 10 minutes. 2.5ml of alkaline phosphatase color developer was 
added to both the tubes and read spectrophotometrically at 590nm [22]. 
2.6.4 Screening for Rubella Antibody (Rubella IgM) 
Rubella virus antibody was analyzed using enzyme-linked immunosorbent assay (ELISA) which is the most 
sensitive and reliable procedure for detection of antibodies to Rubella [23]. 
• Procedure  
Each serum sample was diluted 1:40 with serum diluent and placed in the 93 microwells of the microtitre plate 
and then incubated at room temperature for 30 minutes. About 100µl of negative control, low positive and high 
positive standards were added in separate microwells. The preparation was washed three times and another 
100µl of enzyme conjugate was dispensed into each well and incubated at room temperature for 30 minutes. 
This was then washed three times again and followed by the addition of 100µl Tetramethylbenzidine (TMB 
substrate) into each well and incubated at room temperature for 30mins. The reaction was stopped by the 
addition of 100µl of stop solution. The test was repeated 4 times. The color intensity of the solution in each well 
was measured using a microwell reader with a 450 nm filter [24]. 
3.  Results 
From the 288 sera samples screened, 31 were sero – reactive for HBsAg while 50 were reactive to rubella IgM 
antibody and 2 were sero – reactive to HIV. The overall prevalence for HBsAg was found  to be (10.76%), of 
the 31 HVB sero-positive subjects, 15 (5.22%) were from the 20 – 24 years age bracket representing the most  
susceptible age group while the sero-positivity rate decline in 35 – 39, 40 – 44 and 45 – 49 years age groups 
respectively (Table 3.1). 
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Table 3.1: Summary of Overall Virological Assay 
                                Serological Testing n = 288                                                              Serological Markers n = 31  
Age  group 
(years) 
No 
screen
ed  
HBsAg 
reactive 
(rapid 
screening) 
HIV 
reactive 
(rapid 
screening) 
Rubella IgM 
reactive 
(ELISA)% 
NO. 
Screened  
HBsAg(+) AntiHBs(+) HBeAg(
+) 
AntiHBe(+) AntiHBc(+) 
15 – 19  12 2 (0.70) 0 (0.00) 2(9.52) 2 (0.70) 2(0.70) 0(0.00) 1(3.23) 2(6.45) 2(6.45) 
20 – 24  115 15(5.22) 0 (0.00) 20(17.40) 15(5.22)  15(5.22) 0(0.00) 2(6.45) 12(38.71) 10(32.26) 
25 – 29 81 7(2.44)  0(0.00)  15(18.52) 7(2.44) 7(2.44) 0(0.00) 0(0.00) 5(16.13) 7(22.58) 
30 – 34  45 5(1.74) 2(0.70) 7(15.56) 5(1.74) 5(1.74) 0(0.00) 0(0.00) 3(9.68) 2(6.45) 
35 – 39 22 1 (0.35) 0(0.00)  5(22.73) 1(0.35) 1(0.35) 0(0.00) 0(0.00) 1(3.22) 2(6.45) 
40 – 44 3 0(0.00) 1(0.35) 1(33.33) 0(0.00)  0(0.00) 0(0.00) 0(0.00) 0(0.00) 0(0.00) 
45 – 49  1 1(0.35) 0(0.00)  0 (0.00) 1(0.35) 1(0.35) 0(0.00) 0(0.00) 1(3.22) 1(3.22) 
Total (%)  288 31(10.76) 2(0.70) 50(17.36) 31(10.76)  31(10.76) 0(0.00) 3(9.68) 24(77.42) 24(77.42) 
Key: 
HBsAg: Hepatitis B surface antigen; Anti HBs: antibody to Hepatitis B surface antigen; HBeAg: h\Hepatitis 
Be antigen; Anti HBe: antibody to HBeAg; Anti – HBc: antibody to \Hepatitis B core antigen.  
Table 3.2 determines liver enzymes activity among the HBsAg sero-positive subjects. Abnormal ALT and AST 
test were elevated in serum samples of subjects with HBsAg (+), and HBeAg (+) groups. However, the 
abnormalities in ALP were found to be non-significantly different between HBsAg (+) and HBeAg (+) VS 
HBsAg (+) and HBeAg (-) groups. The rate of abnormal ALT (70.97%) was higher than that of abnormal AST 
(58.06) and abnormal ALP (32.30) in HBsAg (+) subjects (P = 0.00).  
Table 3.3 indicates Sero-prevalence of Rubella IgM Antibodies among Chronic HVB carriers in relation to 
Obstetric Losses with ages. Obstetric histories among various age groups with respect to rubella IgM sero – 
prevalence was observed. Of the 50 sero – reactive rubella IgM studied, 35 had previous abnormal obstetric 
histories. Abortions had the highest percentage 22(62.86%) with highest prevalence (2.39%) among 30 – 34 
years age group and least (1) (2.86%) in 15 – 19 and 40-44 years age groups.   
Premature delivery was observed to be almost uniform across all the ages, but with 11.40 % prevalence rate. 
Still birth was found to have the same prevalence rate with that of premature delivery but with the highest 
prevalence among 20 – 24 age groups (2.86%). However, congenital anomalies, was found to have the least 
prevalence rate of 5.70%. However, neonatal death had the prevalence rate of 8.60% with decline frequency 
towards the ages of 35 – 49 years (P = 0.02).  
 The comparison of rubella susceptibility with chronic HBV carriers and free subjects (non-carriers) was shown 
in Table 3.4. Rubella susceptibility was found to be 25.81% among the HBV sero-positive subjects as against 
12.91% of HVB free subjects (P=0.03).    
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Table 3.2: Determination of the Liver Enzymes Activity among HBsAg Sero-positive Subjects n = 31 
Mode Number 
Screened 
 
Abnormal 
ALT n (%) 
LiverEnzymes 
 
Abnormal AST 
n (%) 
 
 
 
Abnormal  
ALP n (%) 
HBsAg (+) 31(100) 22 (70.97) 18 (58.06) 10 (32.25) 
HBsAg (+) and HBeAg (+) 3(9.68) 3 (9.68) 2 (6.45) 1 (3.23) 
HBsAg(+) and HBeAg (-) 28(90.32) 12 (38.71) 8 (25.81) 2 (6.45) 
Normal values   0 to 12 u/L 0 to 12 u/L  9 – 22 u/L 
     
 Key:    ALT: Alanine aminotransferase   
            AST:  Aspartate Aminotransfearse   
         ALP: Alkanine Phosphate   
 
Table 3.3: Sero-prevalence of Rubella IgM Antibodies among Chronic HVB carriers in relation to            
Obstetric Losses with ages 
                                                          No. of IgM Seropositivity of Rubella Among Various Age Group (Years) 
Obstetric 
history 
15 – 19 20 – 24 25 – 29 30 – 34 35 – 39 40 – 44 45 – 49 Total (%) 
         
Abortions  1(2.86%) 3(8.57%) 5(14.29%) 8(22. 84%) 4(11.42%) 1(2.86%) 0(0.00%) 22 (62.90) 
Premature 
delivery  
0(0.00%) 1(2.86%) 0(0.00%) 1(2.86%) 1(2.86%) 0(0.00%) 0(0.00%) 4 (11.40) 
Still birth 0(0.00%) 2(5.71%) 1(2.86%) 0(0.00%) 1(2.86%) 0(0.00%) 0(0.00%) 4 (11.40) 
Congenital 
anomalies  
0(0.00%) 1(2.86%) 0(0.00%) 1(2.86%) 0(0.00%) 1(2.86%) 0(0.00%) 2 (5.70) 
Neonatal death  0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 1(2.86%) 1(2.86%) 3 (8.60) 
Total (%) 1(2.86) 7(20.00) 6(17.14) 10(28.57) 7(20.00) 3(8.57) 1(2.86) 35 (100) 
= 0.02) 
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Table 3.4: Comparison of Rubella Susceptibility with HBV Carriers and HBV Free Subjects 
    
4.  Discussions  
It is well known that HBV infection is endemic in Nigeria. Even though studies have been carried out on 
hepatitis B virus infection in different parts of the country, and different sub – groups of individuals, information 
regarding its prevalence in pregnant subjects is scanty especially from the north – eastern region [9].  
The classification of high endemicity for HBV infection has been defined as HBsAg greater than 7.00% in adult 
population [25]. The HBsAg sero-positivity of 10.76% among pregnant women in our study (Table 3.1) shows 
that the North-eastern region as in other parts of Nigeria was found to be endemic for HBV infection. The result 
of this study is in conformity with an earlier finding that sub-Saharan Africa has HBV carrier rate ranging from 
9.00% to 12.00% [26].The sero-prevalence rate of 10.76% for HBV infection in this study is higher than the 
2.90% found in pregnant women in Port Harcourt, South – South Nigeria by [27] 9.60% in Anambra [28], 
8.90% in Ibadan [29], 8.30% in Zaria [30], 8.20% in Ilorin [9]and 6.08% in Lagos [31]. It is also higher than the 
6.2% found women in Sierra Leone [32], the 2.50% found by [33] in pregnant Iranian women and the 1.53% 
found by [34] amongst pregnant women attending government maternity hospitals in Kabul.  
The figure 10.76% from this study was however found to be lower than the 11.00% found by [35] among the 
pregnant women in Makurdi, North – Central Nigeria. It was found to be lower than 11.60% found by [36], 
12.30% in Minna [37], 12.50% in Enugu [38] and the 12.60% found by [39] among pregnant women in 
Maiduguri, North eastern part of the country, and a rural community in North Central region respectively. It is 
also lower than the 13.80% found by [40] in pregnant Senegalese women in Dakar and equally lower than the 
63.30% found by [41] in Jos, North – Central Nigeria. The variation in the sero-prevalence may be due to 
geographical variation and differences in cultural practices.  
                                       Chronic HBV Carriers        Control  
Age group  
(years) 
HBV-Carriers  
(%) 
Rubella 
Susceptibility  
(%) 
HBV non Carriers 
(%) 
Rubella 
Susceptibility (%) 
15 – 19 2 (6.45)  0(0.00) 2 (6.46) 0(0.00) 
20 – 24  15 (48.38) 5 (16.13) 15 (48.38) 2 (6.45) 
25 – 29  7 (22.58) 2 (6.45) 7 (22.58) 1 (3.23) 
30 – 34  5 (16.13) 1 (3.23) 5 (16.13) 1 (3.23) 
35 – 39  1 (3.23) 0(0.00) 1 (3.23) 0(0.00) 
40 – 44  0 (0.00) 0(0.00) 0 (0.00) 0(0.00) 
45 – 49 1 (3.23) 0(0.00) 1 (3.23) 0(0.00) 
Total (%)  31 (100) 8 (25.81) 31 (100) 4 (12.91) 
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Most of the previous studies did not distinguish between recent and past infections; screening for HBsAg alone 
does not fully reflect epidemiology of the disease as it could not indicate a carrier state, viral replication, or 
chronic stage; this study differentiated carriers of HBsAg from those with active infection. The assay for 
serological markers of HBV infection such as anti-HBs, HBe, anti-HBe and anti-HBc was carried out. These 
antigens and their homologous antibodies are considered to be specific markers of the HBV infection [42]. The 
result obtained shows that all the HBV sero-positive samples were also confirmed by the appearance of double 
band in HBsAg hole of the HBV combo test kit. HBsAg was the first to appear after exposure to HBV. Three 
samples (9.68%) were reactive to HBeAg which indicate that there was active viral replication or soluble 
antigen present in the circulation (Table 3.1). Young adult (30-35 years) have been reported to have high rates 
of HBeAg – positivity (28.57%), and the rate of positivity decreased with age and this is in line with the finding 
of [43] which could be due to spontaneous sero – conversion to the antibody against HBeAg. Older carriers have 
been shown to be more likely than younger carriers to clear [43] 
Antibody to HBe appeared to be reactive by (77.42%) (Table 3.1); 24 out of 31 subjects were reactive to anti 
HBe. Presence of anti HBe in serum of HBsAg carrier suggests lower titer of HBV and also to antibody to HBc; 
(77.42) of the samples was equally reactive. This indicates infections with HBV of some undefined time in the 
past, and also it is an indication that the infection was resolved. All the sero-positive HBsAg were non-reactive 
to antibody to HBsAg which signifies that none of the subject acquire the infection as a result of vaccination and 
none of the subject was fully protected as affirmed by [42,44]. 
 The association between the serological markers in HBV sero-positive subjects was measured statistically and 
found significant (P < 0.05).  A high prevalence of HBV infection was found with 20 - 24 years age group 
(5.22%) followed by the 25 – 29 (2.44%) then 30 – 34 years age group (1.74%) (Table 3.1), this prevalence is in 
line with the finding of [9]. This may be because age range of 20 – 34 is the most sexually active and more 
fertile.  
The sero-prevalence rate of 17.36% was reported for rubella in this study (Table 3.1); the subjects studied had 
detectable IgM level which is a marker of recent infection. Detection of IgM was well established as a means of 
diagnosing recent CRS and was recommended by the WHO as the primary test for the laboratory confirmation 
of rubella which is in concordance with the study of [45] with 17.50% prevalence rate and that of [46] with 
17.70% prevalence rate. However, the figure 17.36% is in line with the WHO Worldwide prevalence rate of 
rubella susceptibility (7.5 – 17.40%) [47].The result obtained was found to be higher than 4.20% found in 
pregnant women in Makurdi Benue State [18] and 10.00% also among pregnant women attending antenatal 
clinic Benin Teaching Hospitals [48]. Moreover, [49] and [50], reported 6.50% and 10.38% respectively. 
Whereas [51] has reported rubella IgM positivity to be 26.80%. The difference in the prevalence rates may be 
due to the seasons in which the samples were collected, geographical location, cultural behavior, ethnicity, 
sexual behavior and socio-economic status. The wide variation may also be due to the fact that the study area 
was visited by different group of people from various destinations of multiple ethnicities. 
The study of liver enzymes between various groups with chronic HBV infection showed that the increased liver 
enzymes level were significantly higher in HBsAg (+) (70.97%) when compared with normal values (Table 
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3.2). Moreover, subject positive for both HBsAg and HBeAg were more likely to have abnormal values of liver 
enzymes compared with HBsAg carriers negative for HBeAg. Thus, measurement of aminotransferase levels 
remains the most common and convenient way to identify liver inflammation in patients with chronic HBV 
infection. But the relationship may be better established by serial observation and analysis rather than by simple 
examination of aminotransferase levels as shown by [52]. Liver enzymes were found to have positive 
correlation with HBV sero-positivity which is in conformity with the finding of [56,53]. 
All the women that participated in this study were between the ages of 15 – 47 years. Although the highest 
prevalence was observed in 20 – 24 years age (Table 3.3), statistical analysis indicates that there is no 
significant difference between them (rubella has no relationship with age groups) as P > 0.05. This agree with 
the finding of serologic survey rubella IgM in pregnant in Makurdi which shows that (P > 0.05) and considered 
statistically not significant [18] 
In comparative study conducted at the tip of the research. It was observed that HBV chronic carriers are more 
susceptible to rubella virus infection, (25.81%) of hepatitis B chronic subjects were reactive to rubella IgM 
antibody as against (12.91 %) (Table 3.4). This may be due to the fact that in chronic HBV infection, HBsAg 
and HBeAg or HBsAg and anti HBe persist at elevated levels for at least six months or up to life time in some 
individuals [42]. Chronic carriers of HBsAg may or may not have demonstrable evidence of liver disease. 
Persistent (unresolved) viral hepatitis, a mild benign disease that may follow acute hepatitis B in 8 – 10% of 
adult patients, is characterized by sporadically abnormal aminotransferase values and hepatomegaly. Fulminant 
HBV disease is associated with super infection with some other agents [44].The association between chronic 
HBV and rubella susceptibility was measured and found to be statistically significant (P=0.03). This shows that 
there is strong association between chronic HBV and rubella susceptibility. Although a major section of 
pregnant women in Nigeria are immune, the finding of the study shows that cases of rubella infection still occur 
in Nigeria among pregnant women which is in conformity with the finding of [54]. This dispels the notion 
among many hospital workers who think that rubella is no longer an issue. Nigeria has in its hand opportunity to 
eliminate this virus since the burden is low and the actual susceptible population is small and elimination of 
rubella and CRS is National Public Health Goal [21]. 
5.  Conclusion 
The finding of this study confirms that HBV is endemic among pregnant women attending antenatal clinic, 
Muhammad Abdullahi Wase Specialist Hospital, Kano. The study also demonstrates associations between 
chronic HBV infection and rubella susceptibility among the studied population. Moreover, most people of the 
region are not aware of the aforesaid disease hence vertical transmission is very much possible to occur. 
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